Companies
Instil Bio
TIL platforms — optimised expansion.
- Country
- United States
FDA IND
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Founded | August 2018 | sec.gov |
| Headcount | 17 employees (as of December 31, 2025) | sec.gov |
| Revenue | No revenue generated from product sales to date | globenewswire.com · sec.gov |
| Production site | Tarzana, California (owned, leased to AstraZeneca); Alderley Park, United Kingdom (leased); Thousand Oaks, California (leased) | sec.gov |
| Funding | Raised $380.1 million in net proceeds from inception through 2021; cash, cash equivalents, restricted cash, and marketable securities were $69.9 million as of June 30, 2026 | sec.gov |
| Capacity | No current commercial-scale capacity; focused on research and potential early-stage trials | koalagains.com |
Independent sources: globenewswire.com · koalagains.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| TIL therapy (tumor-infiltrating lymphocytes) | therapeutics-platforms | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.